Pimavanserin (hemitartrate)

Pimavanserin (ACP-103) hemitartrate is a potent 5-HT 2A receptor inverse agonist with pIC50 and pKi of 8.73 and 9.3, respectively.

Product Specifications

CAS Number

[706782-28-7]

Product Name Alternative

ACP-103 (hemitartrate)

UNSPSC

12352005

Hazard Statement

H302, H312, H332

Target

5-HT Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/pimavanserin-hemitartrate.html

Purity

99.91

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : 50 mg/mL (ultrasonic)

Smiles

O=C(O)[C@H](O)[C@@H](O)C(O)=O.O=C(NCC1=CC=C(OCC(C)C)C=C1)N(CC2=CC=C(F)C=C2)C3CCN(C)CC3

Molecular Formula

C25H34FN3O2.1/2C4H6O6

Molecular Weight

502.59

Precautions

H302, H312, H332

References & Citations

[1]Vanover KE, et al. Pharmacological and behavioral profile of N- (4-fluorophenylmethyl) -N- (1-methylpiperidin-4-yl) -N'- (4- (2-methylpropyloxy) phenylmethyl) carbamide (2R,3R) -dihydroxybutanedioate (2:1) (ACP- 103), a novel 5-hydroxytryptamine (2A) receptor inverse agonist. J Pharmacol Exp Ther. 2006 May;317 (2) :910-8.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture)

Scientific Category

Reference compound1

Clinical Information

Launched

Isoform

α-1 microglobulin

Citation 01

BioRxiv. 2023 Jul 31:2023.07.29.551106.|Food Chem Toxicol. 2023 Jun:176:113800.|Nat Commun. 2023 Dec 15;14 (1) :8221.|ACS Chem Neurosci. 2019 Nov 20;10 (11) :4476-4491. |bioRxiv. 2020 Feb.|Department Neuroscience. Virginia Commonwealth University. 2016 Oct.|Int J Clin Exp Med. 2019;12 (8) :10342-10349|Int J Neuropsychopharmacol. 2021 Sep 21;24 (9) :749-757.|J Med Chem. 2023 Jul 13;66 (13) :9057-9075.|Patent. US20200352950A1.|Proc Natl Acad Sci U S A. 2020 Oct 20;117 (42) :26438-26447.|Sci Rep. 2024 Jan 16;14 (1) :1396.